![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: PLPP5 |
Gene summary for PLPP5 |
![]() |
Gene information | Species | Human | Gene symbol | PLPP5 | Gene ID | 84513 |
Gene name | phospholipid phosphatase 5 | |
Gene Alias | DPPL1 | |
Cytomap | 8p11.23 | |
Gene Type | protein-coding | GO ID | GO:0006629 | UniProtAcc | A0A140VK38 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
84513 | PLPP5 | GSM4909281 | Human | Breast | IDC | 4.97e-10 | 3.26e-01 | 0.21 |
84513 | PLPP5 | GSM4909297 | Human | Breast | IDC | 2.83e-25 | 7.80e-01 | 0.1517 |
84513 | PLPP5 | GSM4909298 | Human | Breast | IDC | 2.28e-33 | 6.30e-01 | 0.1551 |
84513 | PLPP5 | GSM4909304 | Human | Breast | IDC | 4.38e-13 | 4.17e-01 | 0.1636 |
84513 | PLPP5 | GSM4909308 | Human | Breast | IDC | 9.16e-14 | 4.67e-01 | 0.158 |
84513 | PLPP5 | GSM4909311 | Human | Breast | IDC | 8.89e-04 | -1.38e-01 | 0.1534 |
84513 | PLPP5 | GSM4909317 | Human | Breast | IDC | 8.26e-21 | 6.57e-01 | 0.1355 |
84513 | PLPP5 | GSM4909319 | Human | Breast | IDC | 6.58e-09 | 1.53e-03 | 0.1563 |
84513 | PLPP5 | brca2 | Human | Breast | Precancer | 1.75e-06 | 2.31e-01 | -0.024 |
84513 | PLPP5 | M1 | Human | Breast | IDC | 6.18e-07 | 4.62e-01 | 0.1577 |
84513 | PLPP5 | NCCBC2 | Human | Breast | DCIS | 9.47e-06 | 5.20e-01 | 0.1554 |
84513 | PLPP5 | NCCBC5 | Human | Breast | DCIS | 1.44e-03 | -8.78e-02 | 0.2046 |
84513 | PLPP5 | P1 | Human | Breast | IDC | 2.87e-05 | 7.69e-03 | 0.1527 |
84513 | PLPP5 | P2 | Human | Breast | IDC | 9.09e-12 | 6.46e-01 | 0.21 |
84513 | PLPP5 | DCIS2 | Human | Breast | DCIS | 1.32e-59 | 1.99e-01 | 0.0085 |
84513 | PLPP5 | LZE2T | Human | Esophagus | ESCC | 2.75e-06 | 5.02e-01 | 0.082 |
84513 | PLPP5 | LZE4T | Human | Esophagus | ESCC | 2.91e-11 | 3.08e-01 | 0.0811 |
84513 | PLPP5 | LZE7T | Human | Esophagus | ESCC | 1.08e-06 | 4.28e-01 | 0.0667 |
84513 | PLPP5 | LZE8T | Human | Esophagus | ESCC | 1.04e-08 | 2.94e-01 | 0.067 |
84513 | PLPP5 | LZE22D1 | Human | Esophagus | HGIN | 1.81e-02 | 1.24e-01 | 0.0595 |
Page: 1 2 3 4 5 6 7 8 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001631110 | Esophagus | ESCC | dephosphorylation | 251/8552 | 417/18723 | 1.26e-09 | 2.99e-08 | 251 |
GO:00066446 | Esophagus | ESCC | phospholipid metabolic process | 218/8552 | 383/18723 | 5.37e-06 | 5.59e-05 | 218 |
GO:00302586 | Esophagus | ESCC | lipid modification | 116/8552 | 212/18723 | 4.90e-03 | 1.89e-02 | 116 |
GO:003025811 | Liver | Cirrhotic | lipid modification | 75/4634 | 212/18723 | 3.33e-04 | 2.87e-03 | 75 |
GO:001631111 | Liver | Cirrhotic | dephosphorylation | 130/4634 | 417/18723 | 1.58e-03 | 1.03e-02 | 130 |
GO:00066444 | Liver | HCC | phospholipid metabolic process | 214/7958 | 383/18723 | 7.25e-08 | 1.48e-06 | 214 |
GO:001631121 | Liver | HCC | dephosphorylation | 230/7958 | 417/18723 | 1.00e-07 | 1.96e-06 | 230 |
GO:003025821 | Liver | HCC | lipid modification | 123/7958 | 212/18723 | 3.50e-06 | 4.58e-05 | 123 |
GO:00163119 | Oral cavity | OSCC | dephosphorylation | 220/7305 | 417/18723 | 6.33e-09 | 1.34e-07 | 220 |
GO:00066445 | Oral cavity | OSCC | phospholipid metabolic process | 175/7305 | 383/18723 | 4.21e-03 | 1.71e-02 | 175 |
GO:00163118 | Prostate | BPH | dephosphorylation | 98/3107 | 417/18723 | 1.53e-04 | 1.35e-03 | 98 |
GO:001631113 | Prostate | Tumor | dephosphorylation | 98/3246 | 417/18723 | 7.31e-04 | 5.08e-03 | 98 |
GO:001631116 | Thyroid | PTC | dephosphorylation | 174/5968 | 417/18723 | 1.20e-05 | 1.31e-04 | 174 |
GO:001631117 | Thyroid | ATC | dephosphorylation | 179/6293 | 417/18723 | 3.88e-05 | 3.15e-04 | 179 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa005615 | Liver | HCC | Glycerolipid metabolism | 41/4020 | 63/8465 | 3.59e-03 | 1.12e-02 | 6.22e-03 | 41 |
hsa0056112 | Liver | HCC | Glycerolipid metabolism | 41/4020 | 63/8465 | 3.59e-03 | 1.12e-02 | 6.22e-03 | 41 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PLPP5 | SNV | Missense_Mutation | c.685C>T | p.Arg229Trp | p.R229W | Q8NEB5 | protein_coding | deleterious(0.01) | possibly_damaging(0.662) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
PLPP5 | SNV | Missense_Mutation | rs752975833 | c.691T>G | p.Tyr231Asp | p.Y231D | Q8NEB5 | protein_coding | deleterious(0) | probably_damaging(0.983) | TCGA-D1-A16Y-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PLPP5 | SNV | Missense_Mutation | novel | c.620N>C | p.Lys207Thr | p.K207T | Q8NEB5 | protein_coding | deleterious(0.03) | possibly_damaging(0.906) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PLPP5 | SNV | Missense_Mutation | novel | c.716A>T | p.Glu239Val | p.E239V | Q8NEB5 | protein_coding | tolerated(0.24) | benign(0.009) | TCGA-22-1016-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
PLPP5 | SNV | Missense_Mutation | novel | c.461N>A | p.Ser154Tyr | p.S154Y | Q8NEB5 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-85-6561-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | cisplatin | SD |
PLPP5 | SNV | Missense_Mutation | c.634N>T | p.Asp212Tyr | p.D212Y | Q8NEB5 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-BR-8368-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
PLPP5 | SNV | Missense_Mutation | c.79A>G | p.Thr27Ala | p.T27A | Q8NEB5 | protein_coding | tolerated(0.08) | benign(0.146) | TCGA-CD-A4MG-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
PLPP5 | SNV | Missense_Mutation | novel | c.389N>A | p.Ser130Tyr | p.S130Y | Q8NEB5 | protein_coding | tolerated(0.83) | benign(0.009) | TCGA-HF-A5NB-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | fluorouracil | SD |
PLPP5 | SNV | Missense_Mutation | novel | c.406N>T | p.Gly136Trp | p.G136W | Q8NEB5 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-MX-A5UJ-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |